Back to search results

WATCH Study: Monitoring Heart Health in Lymphoma and Sarcoma Survivors

This study, called WATCH, is looking at new ways to monitor heart health in people who have had lymphoma or sarcoma and were treated with anthracycline-based therapy. Researchers want to see if using mobile devices like Apple Watches and Kardia devices, along with artificial intelligence (AI)-powered electrocardiograms (ECGs), can reliably detect heart problems early. You would have standard heart tests like echocardiograms and ECGs, and some participants would receive an Apple Watch to use. The study aims to find a cost-effective way to prevent heart failure in cancer survivors. To join, you must be at least 18 years old, have lymphoma or sarcoma, and either be starting anthracycline therapy or be one year past completing it. The study will be considered successful if these mobile devices can detect a heart pumping problem (left ventricular ejection fraction or LVEF) of less than 50% within one year.

Study design
This is an interventional study with a planned enrollment of 250 participants. It is not specified if it is randomized or blinded.
What's involved
You would have standard 12-lead ECGs, 6-lead Kardia ECGs, and 1-lead Apple Watch ECGs. You would also have echocardiograms and a limited LVEF echocardiogram, plus blood draws. This would occur from before treatment, throughout treatment, and up to one year after treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up to one year after completing anthracycline-based therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07058064

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

Recruiting
NAAges 18+InterventionalScreening
Mayo Clinic
~250 participants
Updated 2025-10-15 on ClinicalTrials.gov
What's tested:ElectrocardiogramEchocardiogramLVEF echocardiogramApple WatchBiospecimen collectionQuestionnaires

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Detection of left left ventricular ejection fraction (LVEF) <50% by AI-ECG
Measured over Baseline to 1 year follow-up
+2 more outcomes measured

Conditions

Lymphoma
Sarcoma

Explore related trials

LymphomaSarcoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Joerg Herrmann, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Tera Peck
[email protected]
507-266-2123
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ability to understand study procedures and being willing to comply with them for the entire study length
diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy

Exclusion

LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm
Unwilling or unable to give written informed consent
Participants who have opted out of the Minnesota Research Authorization

What this trial measures

  • Detection of left left ventricular ejection fraction (LVEF) <50% by AI-ECGBaseline to 1 year follow-up

    Mobile device ECGs will be compared to standard 12-lead clinic ECGs for the AI algorithm to predict a reduced EF (EF \<50%).

  • Change in AI-ECG based probability of an LVEF <50% using mobile device ECGsBaseline to 1 year follow-up

    The change in probability of abnormal LVEF by AI-ECG using mobile device ECG will be compared between patients who do develop a reduction in LVEF over time versus those who do not.

  • Change in peak VO2Baseline to 1 year follow-up

    Volume of Oxygen (VO2) will be estimated by the Apple Watch algorithm (developed by Apple Inc.) and reviewed for change from baseline to 1 year.